» Articles » PMID: 35887312

Structural Basis of Mutation-Dependent P53 Tetramerization Deficiency

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Jul 27
PMID 35887312
Authors
Affiliations
Soon will be listed here.
Abstract

The formation of a tetrameric assembly is essential for the ability of the tumor suppressor protein p53 to act as a transcription factor. Such a quaternary conformation is driven by a specific tetramerization domain, separated from the central DNA-binding domain by a flexible linker. Despite the distance, functional crosstalk between the two domains has been reported. This phenomenon can explain the pathogenicity of some inherited or somatically acquired mutations in the tetramerization domain, including the widespread R337H missense mutation present in the population in south Brazil. In this work, we combined computational predictions through extended all-atom molecular dynamics simulations with functional assays in a genetically defined yeast-based model system to reveal structural features of p53 tetramerization domains and their transactivation capacity and specificity. In addition to the germline and cancer-associated R337H and R337C, other rationally designed missense mutations targeting a significant salt-bridge interaction that stabilizes the p53 tetramerization domain were studied (i.e., R337D, D352R, and the double-mutation R337D plus D352R). The simulations revealed a destabilizing effect of the pathogenic mutations within the p53 tetramerization domain and highlighted the importance of electrostatic interactions between residues 337 and 352. The transactivation assay, performed in yeast by tuning the expression of wild-type and mutant p53 proteins, revealed that p53 tetramerization mutations could decrease the transactivation potential and alter transactivation specificity, in particular by better tolerating negative features in weak DNA-binding sites. These results establish the effect of naturally occurring variations at positions 337 and 352 on p53's conformational stability and function.

Citing Articles

In Silico Screening, Molecular Dynamics Simulation and Binding Free Energy Identify Single-Point Mutations That Destabilize p53 and Reduce Binding to DNA.

Islam S, Hasan M, Alam J, Dey A, Molineaux D Proteins. 2024; 93(2):498-514.

PMID: 39264222 PMC: 11695177. DOI: 10.1002/prot.26747.


How Do Cancer-Related Mutations Affect the Oligomerisation State of the p53 Tetramerisation Domain?.

Nicolini F, Todorovski T, Puig E, Diaz-Lobo M, Vilaseca M, Garcia J Curr Issues Mol Biol. 2023; 45(6):4985-5004.

PMID: 37367066 PMC: 10296842. DOI: 10.3390/cimb45060317.

References
1.
Bykov V, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P . Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002; 8(3):282-8. DOI: 10.1038/nm0302-282. View

2.
Mullard A . p53 programmes plough on. Nat Rev Drug Discov. 2020; 19(8):497-500. DOI: 10.1038/d41573-020-00130-z. View

3.
Gomes A, Ramos H, Inga A, Sousa E, Saraiva L . Structural and Drug Targeting Insights on Mutant p53. Cancers (Basel). 2021; 13(13). PMC: 8268744. DOI: 10.3390/cancers13133344. View

4.
Gordo S, Martos V, Santos E, Menendez M, Bo C, Giralt E . Stability and structural recovery of the tetramerization domain of p53-R337H mutant induced by a designed templating ligand. Proc Natl Acad Sci U S A. 2008; 105(43):16426-31. PMC: 2575436. DOI: 10.1073/pnas.0805658105. View

5.
Raj N, Attardi L . The Transactivation Domains of the p53 Protein. Cold Spring Harb Perspect Med. 2016; 7(1). PMC: 5204331. DOI: 10.1101/cshperspect.a026047. View